AB0360 EFFICACY AND SAFETY OF THE PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST CR6086 ADDED TO METHOTREXATE IN DMARD-NAÏVE EARLY RA PATIENTS: A PHASE 2 RANDOMIZED CONTROLLED TRIAL

MLA

M. Krogulec, et al. “Ab0360 Efficacy and Safety of the Prostaglandin Ep4 Receptor Antagonist Cr6086 Added to Methotrexate in Dmard-Naïve Early Ra Patients: A Phase 2 Randomized Controlled Trial.” Annals of the Rheumatic Diseases, vol. 79, June 2020, p. 1480.1-1481. EBSCOhost, https://doi.org/10.1136/annrheumdis-2020-eular.5636.

APA

M. Krogulec, Massimo D’Amato, Minodora Mazur, Peter C. Taylor, A. R. Bihlet, G. Giacovelli, Olga Kubassova, R. Østgård, Lucio C. Rovati, F. Girolami, Karel Pavelka, & I. D. Delina. (2020). Ab0360 Efficacy and Safety of the Prostaglandin Ep4 Receptor Antagonist Cr6086 Added to Methotrexate in Dmard-Naïve Early Ra Patients: A Phase 2 Randomized Controlled Trial. Annals of the Rheumatic Diseases, 79, 1480.1-1481. https://doi.org/10.1136/annrheumdis-2020-eular.5636

Chicago

M. Krogulec, Massimo D’Amato, Minodora Mazur, Peter C. Taylor, A. R. Bihlet, G. Giacovelli, Olga Kubassova, et al. 2020. “Ab0360 Efficacy and Safety of the Prostaglandin Ep4 Receptor Antagonist Cr6086 Added to Methotrexate in Dmard-Naïve Early Ra Patients: A Phase 2 Randomized Controlled Trial.” Annals of the Rheumatic Diseases 79 (June): 1480.1-1481. doi:10.1136/annrheumdis-2020-eular.5636.